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Abstract
Background: Little is known about the molecules that contribute to tumor progression of epithelial
ovarian cancer (EOC), currently a leading cause of mortality from gynecological malignancies.
Glucocorticoid-Induced Leucine Zipper (GILZ), an intracellular protein widely expressed in immune
tissues, has been reported in epithelial tissues and controls some of key signaling pathways involved in
tumorigenesis. However, there has been no report on GILZ in EOC up to now. The objectives of the
current study were to examine the expression of GILZ in EOC and its effect on tumor cell proliferation.
Results: GILZ expression was measured by immunohistochemical staining in tissue sections from 3
normal ovaries, 7 benign EOC and 50 invasive EOC. GILZ was not detected on the surface epithelium of
normal ovaries and benign tumors. In contrast, it was expressed in the cytoplasm of tumor cells in 80%
EOC specimens. GILZ immunostaining scores correlated positively to the proliferation marker Ki-67
(Spearman test in univariate analysis, P < 0.00001, r = 0.56). They were also higher in tumor cells containing
large amounts of phosphorylated protein kinase B (p-AKT) (unpaired t test, P < 0.0001). To assess the
effect of GILZ on proliferation and AKT activation, we used the BG-1 cell line derived from ovarian tumor
cells as a cellular model. GILZ expression was either enhanced by stable transfection or decreased by the
use of small interfering (si) RNA targeting GILZ. We found that GILZ increased cell proliferation,
phospho-AKT cellular content and AKT kinase activity. Further, GILZ upregulated cyclin D1 and
phosphorylated retinoblastoma (p-Rb), downregulated cyclin-dependent kinase inhibitor p21, and
promoted the entry into S phase of cell cycle.
Conclusion: The present study is the first to identify GILZ as a molecule produced by ovarian cancer
cells that promotes cell cycle progression and proliferation. Our findings clearly indicate that GILZ
activates AKT, a crucial signaling molecule in tumorigenesis. GILZ thus appears as a potential key molecule
in EOC.
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Background
Epithelial ovarian cancer (EOC) accounts for nearly 90%
of ovarian malignant tumors [1,2]. Early stage ovarian car-
cinoma is silent in nature and therefore these carcinoma
often expand into the peritoneal cavity and metastasize to
the omentum before diagnosis. Consequently, treatment
is particularly challenging and this malignancy is a lead-
ing cause of death among gynecological malignancies in
developed countries [3]. The prognosis for patients with
ovarian carcinoma is determined by conventional criteria,
including tumor stage, histological type, and grade.
Indeed, there is also a need to identify molecular markers
that drive ovarian tumor progression, one of the least
determined process in cancer research, to offer novel, tar-
geted, biological therapy [4].
Glucocorticoid-Induced Leucine Zipper (GILZ) is a small
leucine zipper protein of 17 kDa and a member of the
TSC22D (Transforming Growth Factor1 Stimulated Clone
22 Domain) family of proteins also known as TSC22D3.
GILZ was discovered as a dexamethasone-induced tran-
script in murine thymocytes [5]. It is widely expressed in
immune tissues and has also been reported in epithelial
tissues often associated to a hormonal background. It is
rapidly induced by glucocorticoids in T lymphocytes [6-
8], macrophages, dendritic cells and mast cells [9-11].
GILZ expression in the anterior pituitary during embry-
onic development in the chick is consistent with regula-
tion by corticosteroids [12]; in the kidney cortical
collecting duct, GILZ is induced by aldosterone [13]; and
in human cervical adenocarcinoma HeLa cells, GILZ
expression is controlled by estradiol [14].
GILZ interferes with Raf-1, nuclear factor-kB (NF-kB), AP-
1 and FoxO forkhead transcription factor FoxO3
[15,8,16,17], all are key signaling molecules important for
tumorigenesis [18]. There have, however, been few studies
of GILZ in cancer. GILZ has been reported in multiple
myeloma, in lymphoblastic leukemia and in human oste-
osarcoma cells [19-22]. Most relevant work has been in
cell lines and very few data from human tumor specimens
are available. To our knowledge, there is no report on
GILZ in EOC. We therefore investigated GILZ expression
and function in these malignant tumors. Our findings are
supported by parallel and complementary data accumu-
lated in tumor specimens and in the BG-1 cellular model.
We report evidence that GILZ, an intracellular factor not
previously described in EOC, plays a pivotal role in tumor
cell proliferation.
results
GILZ detection in human ovarian tumor samples
GILZ expression was assessed by immunohistochemical
staining of sections isolated from three normal ovaries,
seven benign EOC and 50 invasive EOC. GILZ was not
detected on the surface epithelium of normal ovaries and
in benign tumors. In contrast, among the invasive ovarian
cancers, 40 (80%) expressed GILZ. GILZ immunoreactiv-
ity was detected in the four main histological subtypes,
serous, clear cell, endometrioid and mucinous tumors. It
was clearly confined to the cytoplasm of tumor cells and
was weak in, or absent from the tumor stroma (Figure 1A
and 1B). Using the same antibody, we detected GILZ pro-
tein by western blot. GILZ was revealed at 17 kDa, which
is the size of the protein described by Ricardi and co-work-
ers in 1997 [5], in BG-1 cells transfected with the GILZ-
encoding vector pcDNA3-GILZ (pGILZ BG-1 cells used as
positive control), in epithelial cells from malignant ascites
and in ovarian tumor samples for which frozen tissues
were available, confirming the staining data (Figure 1C).
Interestingly, the non-epithelial cells from malignant
ascites do not express GILZ. GILZ 17 kDa protein was also
detected in ovarian cancer cell lines SKOV-3, OVCAR-3
and BG-1; it was less abundant in BG-1 cell line than in
SKOV-3 and OVCAR-3 (Figure 1C). BG-1 thus appeared as
the best-fitted cellular model for processing up and down
regulation of GILZ.
GILZ expression correlates with tumor cell proliferation 
and with the expression levels of phospho-AKT in EOC
GILZ immunostaining was unevenly distributed in tumor
cells, from no detectable staining to strong immunoreac-
tivity. We asked if differences in GILZ expression levels are
related to the expression of two markers, the proliferation
marker Ki-67 used in routine diagnostics [23] and p-AKT
used to characterize malignant ovarian tumors [24].
Hyperactivation of AKT is frequently observed in ovarian
neoplasms and is related to the control of cell prolifera-
tion in EOC [25,26]. Immunoreactivity of GILZ, Ki-67
and p-AKT was measured on serial sections of EOC (Fig-
ure 2A). GILZ and Ki-67 immunostainings were scored on
a seven-point scale based on the staining intensity and the
extent of staining. GILZ and Ki-67 expression scores were
significantly correlated in the entire cohort (Spearman test
in univariate analysis, P < 0.00001, r = 0.56) (Figure 2B).
They were still correlated in serous carcinoma and non
serous carcinoma as well (Spearman test in univariate
analysis, P < 0.001, r = 0.61, n = 26 serous carcinoma, P <
0.02, r = 0.49, n = 24 non serous carcinoma). The expres-
sion of p-AKT in tumor cells was mostly cytoplasmic,
although some nuclear staining was also detected (Figure
2A). Both nuclear and cytoplasmic staining patterns were
considered to assess p-AKT immunoreactivity, scored as
high or low. GILZ expression scores were significantly
higher in p-AKThigh specimens (mean ± SE = 5.2 ± 0.2, n =
25) than in p-AKTlow specimens (mean ± SE = 2.6 ± 0.4, n
= 25), (unpaired t test, P < 0.0001) (Figure 2C).
After applying a single cut-off on the entire cohort for
identification of GILZhigh (scores 5-7, n = 24) and GILZlowMolecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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GILZ detection in epithelial ovarian cancer (EOC) Figure 1
GILZ detection in epithelial ovarian cancer (EOC). (A) GILZ immunostaining in ovarian surface epithelium of normal 
ovaries (OSE), benign tumors, invasive serous ovarian carcinoma. Negative control was done without primary Ab. Original 
magnification, ×63. (B) Cytoplasmic GILZ immunostaining in clear cell, endometrioid and mucinous EOC. Original magnifica-
tion, ×40. (C) GILZ immunoblots of total protein lysates from ovarian cancer tissue (representative data from several frozen 
tumor specimens), malignant ascites processed by the autoMacs procedure to separate EpCAM+ cells identified as epithelial 
cells from EpCAM- cells, from ovarian cancer cell lines SKOV-3, OVCAR-3 and BG-1. BG-1 cells stably transfected with GILZ-
encoding vector pcDNA3-GILZ (pGILZ) was used as positive control (17 kDa). Actin levels are shown for normalization. Data 
are representative of three different experiments.Molecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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GILZ expression correlates with p-AKT levels and with cell proliferation in epithelial ovarian cancer (EOC) Figure 2
GILZ expression correlates with p-AKT levels and with cell proliferation in epithelial ovarian cancer (EOC). (A) 
Serial sections of tumors with staining for p-AKT, GILZ and Ki-67. Negative control was done without primary Ab. Original 
magnifications, ×20 and ×63. Pictures show cytoplasmic staining for GILZ and nuclear staining for Ki-67; p-AKT staining is 
mostly in the cytoplasm with some additional nuclear staining (arrow). (B) GILZ and Ki-67 final scores were positively corre-
lated (Spearman test in univariate analysis, P < 0.00001, r = 0.56). (C) GILZ scores for p-AKThigh and p-AKTlow groups (the dif-
ference was significant at P < 0.05, Student's t test). Insets: high and low p-AKT immunoreactivity is shown on representative 
micrographs.Molecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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(scores 0-4, n = 26) cases, we found that high GILZ scores
are associated with higher p-AKT staining and Ki-67
indexes (Fisher test, P < 0.0002 and P < 0.0008), (Table 1).
In contrast, age at diagnosis and distribution of histologi-
cal subtypes did not differ between the two groups (Table
1).
All these observations suggest that GILZ expression may
regulate cell proliferation and AKT phosphorylation in
EOC. To assess this hypothesis and to provide further bio-
logical evidence to support immunohistochemical data,
we performed in vitro experiments using the BG-1 cell line
as a cellular model.
Overexpression of GILZ increases proliferation and AKT 
phosphorylation in BG-1 cells
To study the effect of GILZ on cell proliferation in epithe-
lial ovarian cancer, we generated BG-1 clones that stably
and strongly express GILZ (pGILZ). As a control BG-1 cells
were stably transfected with an empty vector (CTRL).
pGILZ and CTRL clones were randomly selected for fur-
ther experiments. The GILZ protein content was signifi-
cantly higher in pGILZ clones than CTRL clones (Figure
3A). We then compared their spontaneous cell prolifera-
tion: it was significantly higher in pGILZ clones (P < 0.01)
(Figure 3B). To confirm that GILZ overexpression
increased the proliferation rate, CTRL and pGILZ clones
were seeded at equal densities, and viable cells were
counted over a 4-day period. Cells overexpressing GILZ
grew faster than CTRL cells (Figure 3C). There was no dif-
ference in spontaneous apoptosis between pGILZ and
CTRL clones [see Additional file 1].
We next investigated whether over-expression of GILZ
affected AKT activation. p-AKT, currently the active form
of AKT, was more abundant in pGILZ clones than in CTRL
clones, whereas the status of phospho-ERK 1/2 remained
unchanged (Figure 3D). In parallel, AKT activity was
higher in pGILZ clones than in CTRL clones as assessed by
testing for phosphorylation of glycogen synthase kinase
(GSK-3α/β), a downstream target of AKT (Figure 3E).
Thus GILZ overexpression induced an increase in p-AKT
and an enhancement of AKT activity. AKT-binding pro-
teins may cause structural changes and phosphorylations
that activate AKT [27,28]. We also revealed the presence of
GILZ-AKT complexes in BG-1 cells using immunoprecipi-
tation experiments (Figure 3F).
GILZ silencing reduces cell proliferation and AKT 
phosphorylation in BG-1 cells
We studied the effects of knocking down GILZ mRNAs in
BG-1 cells on cell proliferation and AKT activation. Real-
Table 1: GILZ immunostaining scores versus Ki-67 proliferation index and p-AKT immunostaining in ovarian carcinoma tissues (n = 
50)
Patient number Fisher test
Statistical significancea
GILZlow
scores (0-4)
GILZhigh
scores (5-7)
All carcinomas 26 24
Age at diagnosis
< 60 years 13 13 ns
> 60 years 13 11
Histological types
Serous 13 13 ns
Non serous 13 11
Clear cells 3 2 ns
Mucinous 5 4
Endometrioid 4 4
Undifferentiated 1 1
Ki-67 Immuno-staining
low scores (0-4) 23 (88%) 10 (42%) P < 0.0008
high scores (5-7) 3 (12%) 14 (58%)
Phospho-AKT immuno-staining
low 20 (77%) 5 (21%) P < 0.0002
high 6 (23%) 19 (79%)Molecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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time PCR and western blot analyses revealed that siRNA
duplexes efficiently and specifically inhibited the expres-
sion of GILZ (mRNA and protein abundance) more than
75% lower than in cells treated with irrelevant control
siRNA (Figure 4A).
Silencing GILZ gene expression led to a marked inhibition
of cell proliferation and AKT phosphorylation, without
changing phospho-ERK1/2 status (Figure 4, B and 4C).
Down regulation of GILZ expression in OVCAR3 cells, an
ovarian cancer cell line that contains high amount of
GILZ, also resulted in a decrease of cell proliferation [see
Additional file 2]. These various findings reveal a previ-
Up regulation of GILZ increases cell proliferation and AKT activation Figure 3
Up regulation of GILZ increases cell proliferation and AKT activation. (A) Total protein lysates analyzed by western 
bloting with anti-GILZ Ab in two CTRL and pGILZ clones. (B) Cell proliferation measured by [3H]-thymidine incorporation in 
two CTRL and pGILZ clones. Means ± SD of three independent experiments. Statistics used Kruskall Wallis test, *P < 0.05, **P 
< 0.01. (C) Number of trypan blue-excluding cells among CTRL and pGILZ clones seeded at 15 × 103 cells/well and cultured 
for 4 days. Means of triplicates of one representative experiment of three; error bars represent SE. (D) Left: total protein 
lysates from CTRL or pGILZ clones cultured overnight without serum analyzed by western blotting using specific Abs. Right: p-
AKT signal quantified by densitometric analysis and normalized to total AKT. Mean ± SE of three experiments, *P < 0.05, 
unpaired Student's t test. (E) Total lysates from CTRL or pGILZ were immunoprecipitated (IP) using an anti-AKT Ab, and then 
incubated with GSK-3-fusion protein in an in vitro kinase assay. GSK-3 phosphorylation was assessed by western blot (WB) 
with phospho-specific GSK-3 Ab. Total AKT was used for normalization. (F) Total protein lysates from BG-1 cells were 
immnunoprecipitated with anti-AKT Ab or control rabbit IgG, and submitted to western blotting with anti-GILZ Ab. After 
stripping, membranes were reblotted with anti-total AKT mouse Ab. Blots: one representative experiment of three.Molecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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GILZ down-regulation reduces cell proliferation and AKT phosphorylation in BG-1 cells Figure 4
GILZ down-regulation reduces cell proliferation and AKT phosphorylation in BG-1 cells. BG-1 cells were trans-
fected with 4 μg of control (siCT) or GILZ-specific (siGILZ) siRNA. (A) GILZ mRNA assayed by real-time RT-PCR and nor-
malized to β-actin mRNA, 48 h after transfection. Results expressed as percentage of control from three independent 
experiments, mean ± SE. (B) Cell proliferation assayed by [3H]-thymidine incorporation 48 h after transfection with siRNA, 
mean ± SD, unpaired Student's t test was used for comparisons, **P < 0.01. (C) Left: total protein lysates were analyzed by 
western blotting using specific Abs. Blots: one representative experiment of three. Right: p-AKT expression levels were quan-
tified by densitometric analysis and normalized to the signal for total AKT. Histogram represents mean ± SE of three experi-
ments. Unpaired Student's t test was used for comparisons, *P < 0.05.Molecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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ously unappreciated role of GILZ in the regulation of pro-
liferation and AKT activation.
GILZ controls p21 and cyclin D1 expression
The cyclin-dependent kinase inhibitor p21 and cyclin D1
are two AKT targeted proteins that negatively (p21) and
positively (cyclin D1) control cell cycle progression and
proliferation [29]. Cyclin D1 activates cyclin-dependent-
kinases (CDK4/6), leading to phosphorylation of retino-
blastoma (Rb) with the resulting promotion of cell cycle
progression [30]. We found that the overexpression of
GILZ caused the up-regulation of cyclin D1 (mRNA and
protein) and increased the amount of phosphorylated Rb
(p-Rb); in contrast, p21 was down-regulated (Figure 5A).
At the opposite, down regulation of GILZ resulted in
decreased amount of cyclin D1 gene products (mRNA and
protein) and p-Rb whereas those of p21 increased (Figure
GILZ controls cyclin D1 and p21 expression Figure 5
GILZ controls cyclin D1 and p21 expression. (A) Left: cyclin D1, phosphorylated retinoblastoma (p-Rb) and p21 were 
measured by western blot in CTRL and in pGILZ clones. β-actin was used as a loading control. Right: the steady-state levels of 
cyclin D1 and p21 mRNAs were assayed by semi-quantitative RT-PCR in CTRL and in pGILZ clones; β-actin was used as a 
loading control. (B) p21 and cyclin D1 gene products were measured by western blot (left) or by semi-quantitative RT-PCR 
(right) 48 h after BG-1 cells were transfected with 4 μg of control (siCT) or GILZ-specific (siGILZ) siRNA; β-actin was used as 
a loading control. Blots: one representative experiment of three. (C) Top: CTRL and pGILZ clones were synchronized by dou-
ble thymidine block. Following removal of the block, cells were analyzed for DNA content by PI staining and cell cycle distribu-
tion was analyzed by flow cytometry at various time points; the percentages of cells in different cycle phases were determined 
by ModFit Cell Cycle Analysis software. Data are representative of three independent experiments. Bottom:Percentage of cells 
in each phase of the cell cycle. Results from three independent experiments (mean ± SE). Unpaired Student's t test was used 
for comparisons.Molecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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5B). Thus the effects of down regulation of GILZ mirrored
those of overexpression.
GILZ caused changes in p21 and cyclin D1 expression in
such a way that increases in GILZ expression would accel-
erate cell cycle progression. To confirm this prediction we
analyzed the cell cycle distribution of synchronized cells
following removal of the thymidine block. We found that
pGILZ cells entered S phase earlier than CTRL cells (Figure
5C).
AKT activation contributes to BG-1 cell proliferation
To investigate whether AKT activation is required for con-
trol of BG-1 cell proliferation, we used Triciribine, a spe-
cific pharmacological inhibitor of AKT phosphorylation.
Triciribine treatment (5-20 μM) reduced p-AKT levels and
in parallel decreased spontaneous proliferation of pGILZ
and CTRL clones (Figure 6A). These findings indicate that
AKT phosphorylation contributes to BG-1 cell prolifera-
tion. Further, Triciribine also caused an up-regulation of
p21 expression in both CTRL and pGILZ clones. Interest-
ingly, cyclin D1 expression remained unchanged. In addi-
tion, GILZ levels remained unchanged suggesting that p-
AKT inhibition did not significantly affect GILZ expres-
sion (Figure 6B).
These various experiments show that AKT activation con-
trols the expression level of p21 and contributes to cell
proliferation in BG-1 cells. The enhancement of AKT acti-
vation by GILZ therefore accounts for GILZ effect, at least
in part, on cell proliferation. In contrast, the enhancement
of cyclin D1 promoted by GILZ is disconnected of its
action on AKT.
Discussion
The effects of GILZ have been mostly described in
immune cells, particularly T-lymphocytes [17] or den-
dritic cells [10]. The role of GILZ in cancer is still poorly
understood and most relevant work has been done in cell
lines [19-22]. Here, we identified GILZ as a significant fac-
tor in the control of tumor cell proliferation in EOC.
This is the first report of the constitutive expression of
GILZ in ovarian tumor specimens from patients with inva-
sive ovarian carcinoma. Epithelial cells from malignant
ascites, tumor specimens, and the ovarian cancer cell lines
SKOV-3, OVCAR-3 and BG-1, all contain GILZ with a
molecular weight of 17 kDa which is the original variant
described by Riccardi and co-workers in 1997 [5].
Although contrasting views of the origin and histogenesis
of EOC have been proposed, the epithelium that lines the
ovarian surface is traditionally considered to be the most
common origin of the neoplastic transformation [1,31].
Here, we did not detect GILZ on the surface epithelium of
normal ovaries or in benign tumors, whereas it was
expressed in most of EOC specimens, suggesting that
GILZ is a molecule associated with malignant processes in
ovaries. Ovarian epithelial tumors generally display mor-
phological heterogeneity that pathologists classify into
serous, clear cell, endometrioid, and mucinous subtypes
on the basis of histopathological examination. Each sub-
type is characterized by specific genetic risk factors, molec-
ular features, and mRNA expression profiles [32-34],
suggesting that ovarian carcinoma is a heterogeneous dis-
ease [35]. Despite this heterogeneity, GILZ was detected in
all the well-defined histological types and appears to be
widely expressed in EOCs, and not restricted to particular
histological subtypes.
GILZ was clearly confined to the cytoplasm in ovarian
tumor cells. The intensity of GILZ staining and the pro-
portion of tumor cells that were stained for GILZ differed
between tumor sections. We found that this uneven pro-
duction of GILZ in EOC correlated with the expression
levels of Ki-67 when all the tumors were considered and
also when the serous group was only considered. These
findings were further supported by in vitro data demon-
strating that tumor cell proliferation is regulated by GILZ
expression level. Along with Ki-67, GILZ correlated with
p-AKT, commonly used to characterize malignant tumor
cells [23,24]. These findings were supported by in vitro
data demonstrating that GILZ enhances p-AKT level and
AKT activity. The PI3K/AKT pathway transmits mitogenic
signals and controls cell cycle progression in ovarian can-
cer cells [26]. We found that p-AKT, the active form of
AKT, accumulated in strongly positive GILZ tumor speci-
mens. Further, up and down regulation of GILZ in BG-1
cells grown in vitro promoted parallel changes in the cel-
lular abundance of p-AKT and in cell proliferation. In con-
trast, there was no feed back control of GILZ expression by
p-AKT, unlike what has recently been reported in multiple
myeloma [19]. AKT is frequently hyperactivated in EOC
and contributes to the pathogenesis of ovarian cancer
[25,36,37]. However, little is known about intracellular
molecules that control AKT activation in tumor cells. Pro-
tein-protein interactions between GILZ and Raf and
between GILZ and Ras have been reported in primary
spleen T Lymphocytes and thymocytes [15,38]. As a con-
sequence, GILZ inhibits downstream AKT cascades lead-
ing to antiproliferative effects in these cells. In contrast,
our data are consistent with a model in which GILZ acti-
vates AKT and promotes cell proliferation. These findings
probably reflect the large spectrum of GILZ actions and
how they may differ substantially according to cell type
and physio-pathological conditions. We also reveal the
presence of GILZ-AKT complexes in BG-1 cells, suggesting
that GILZ may be a novel partner of AKT. AKT-interacting
proteins that bind to different functional domains have
been widely reported [27]. They cause phosphorylationsMolecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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AKT activation is required for BG-1 cell proliferation Figure 6
AKT activation is required for BG-1 cell proliferation. (A) Cell proliferation was measured by [3H]-thymidine incorpo-
ration in CTRL and pGILZ clones treated with indicated Triciribine doses for 24 h. Results are means ± SE of 3 independent 
experiments. (B) western blots of total protein lysates from CTRL or pGILZ clones treated with indicated Triciribine doses for 
24 h. Membranes were probed with specific antibodies. The expression of GILZ, p-AKT, cyclin D1 and p21 proteins were 
quantified by densitometric analysis and normalized to β-actin or total AKT; results are expressed as GILZ/β-actin, p-AKT/
AKT, cyclin D1/β-actin or p21/β-actin ratios. Blots: one representative experiment of three.Molecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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and/or structural changes that activate AKT and lock it in
an active conformation. Our findings suggest that GILZ
may provide intrinsic signals for AKT activation in the
absence of external stimulation. Further studies will be
needed to determine the precise molecular mechanisms
underlying GILZ/AKT interaction.
Most of the G1-S regulators which control the G1-S tran-
sition, a crucial step in cell cycle progression, play also an
important role in the tumor progression. Cyclin D1 is a
positive regulator of progression through the G1 phase of
the cell cycle. The transition to S phase is triggered by the
activation of the cyclin D/CDK complex, which phospho-
rylates Rb, a well known regulator of cell proliferation
[30]. At the opposite, p21, a universal CDK inhibitor, pre-
vents cell cycle progression by acting at checkpoint G1
that causes sustained G1 blockade [29]. Importantly, we
reveal that GILZ increases cyclin D1 expression and the
amount of p-Rb, the essential substrate of cyclin D-CDK4/
6 complex, whereas at the opposite it decreases p21
expression. All these effects that have never been reported
before, are consistent with GILZ action on S-phase entry.
Using Triciribine, a pharmacological inhibitor of AKT acti-
vation, we reveal that BG-1 cell proliferation depends on
AKT phosphorylation. In the same time we reveal that p21
which is negatively regulated by GILZ, is also reduced by
AKT activation. This is consistent with a possible control
of p21 expression by AKT as previously reported in vari-
ous cell types [39]. Thus, GILZ-mediated enhancement of
AKT activity may contribute to decrease p21 and to pro-
mote cell proliferation. In contrast, AKT is not required for
cyclin D1 up regulation in BG-1 cells unlike what has
been reported up to now in other cell types [40,41]. Pos-
sibly, GILZ may directly control the transcriptional activ-
ity of cyclin D1 as already demonstrated for other
molecules [42].
Conclusion
Few studies have identified particular molecules and their
roles in the molecular mechanisms of tumor progression
in EOC. Here, we report a previously unsuspected and
important role for GILZ in the control of tumor cell pro-
liferation in EOC. Our findings were supported by parallel
and complementary data from tumor specimens and
work with the BG-1 cellular model. They demonstrate
that, in EOC, GILZ increases tumor cell proliferation, acti-
vates AKT, down-regulates p21 and promotes cyclin D1
expression; all these molecules are involved in the pro-
gression of malignant tumors and their deregulations are
often associated to poor clinical outcome [43-46,25].
These findings highlight GILZ as a potential key molecule
in EOC.
Materials and methods
Tissue samples
Approval was obtained from the ethics commission of the
Antoine Béclère Hospital (Clamart, France) for all analy-
ses of tumor material from clinical samples and from
archival material from patients with a diagnosis of inva-
sive ovarian carcinoma. Immunohistochemical examina-
tion of GILZ, phosphorylated protein kinase B/AKT (p-
AKT) and Ki-67 proliferation index was performed retro-
spectively on tissue specimens of primary invasive ovarian
carcinomas taken for routine diagnostic and therapeutic
purposes from 50 patients who were treated surgically fol-
lowing a diagnosis of ovarian tumor at Antoine Béclère
Hospital between 1998 and 2007. Clinical and patholog-
ical characteristics of the patients are detailed in Table 2.
None of the patients had received neo-adjuvant chemo-
therapy before surgery. Clinical stage was assigned accord-
ing to the International Federation of Gynecology and
Obstetrics staging system (FIGO); histological subtypes
and grades were assigned according to the criteria of the
World Health Organization (WHO) classification [47].
Immunohistochemistry
We tested for GILZ, Ki-67 and p-AKT in EOC samples. Par-
affin-embedded tissue sections were cut from representa-
tive blocks of tumor biopsies and probed with the
following antibodies by the avidin-biotin peroxidase
method (LSAB kit, Dako-France, Trappes): GILZ polyclo-
nal antibody (Ab) (Santa Cruz, Le Perray-en-Yvelines,
France, 1:100), Ki-67 monoclonal (m)Ab (Dako, 1:50)
and phospho-AKT(ser473) Ab (Cell Signaling, St quentin-
en-Yvelines, 78053, France, 1:50) which recognizes only
the phosphorylated form of AKT [25,48]. Antigens were
unmasked by incubation in 10 mmol/L sodium citrate
buffer (Dako) and heating at 90°C using a microwave
oven. Tissues were counterstained with hematoxylin. Neg-
ative controls were done without the primary Ab. Immu-
nochemical staining was simultaneously interpreted by
two independent investigators without knowledge of the
patients' clinicopathological outcome. Immunostaining
for GILZ and for Ki-67 were scored on a seven-tiered scale
as follows: negative (0), 1 (weak intensity), 2 (moderate
intensity) or 3 (strong intensity) combined with the per-
centage of positive cells scored as 0 (0%), 1 (1-10%), 2
(10-50%), 3 (50-80%), 4 (>80%) as previously reported
[49]. P-AKT immunoreactivity was scored as low versus
high, because sections with high AKT kinase activity have
been reported to immunoreact strongly with phospho-
AKT (ser473) Ab, presumably reflecting overexpression of
the PI3K/AKT pathway, whereas no or weak p-AKT immu-
nostaining has been described in tumor samples without
increased AKT activity [49,50].Molecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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Tumor cell enrichment from ascites
Tumor cell enrichment was based on the expression of
CD326, a human epithelial antigen also known as
EpCAM, which is broadly expressed on cells of epithelial
origin and derived tumor cells [51]. CD326+ cells were
positively selected using autoMACs columns (Myltenyi
Biotech, Paris, France) from ascites collected from patients
diagnosed with EOC. The percentage of CD326+ cells in
the positive fraction was more than 80% as assessed using
a FACScan flow cytometer (BD Biosciences).
Cell culture and reagents
BG-1 cells derived from a solid tumor tissue of a patient
with stage III ovarian adenocarcinoma (a kind gift from
Dr G. Lazennec, U844 Inserm Montpellier, France) were
maintained in Dulbecco's modified minimum essential
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 2 mmol/L L-glutamine, 0.1 mg/mL strepto-
mycin and 100 U/mL penicillin (Invitrogen, Ilkirch,
France). The human ovarian carcinoma cell lines SKOV-3
and OVCAR-3 (American Type Culture Collection) were
maintained in RPMI 1640 medium containing 0.1 mg/mL
streptomycin, 100 U/mL penicillin, 2 mmol/L L-
glutamine and 10% FBS. Triciribine was purchased from
Calbiochem (VWR International SAS, Fontenay-sous-
bois, France).
Generation of BG-1 clones stably overexpressing GILZ
BG-1 cells were transfected using jetPEI (Polyplus-trans-
fection, France) according to the manufacturer's protocol,
with the GILZ-encoding vector pcDNA3-GILZ or with the
empty vector pcDNA3 as a control. Forty-eight hours after
transfection, stably transfected cells were selected by a 2-
week treatment with 500 μg/mL of Geneticin (G-418; Inv-
itrogen) and cloned by limiting dilution. Clones were
then screened for GILZ expression using quantitative real-
time PCR and immunoblot assays. GILZ expression
remained stable over 7 days in culture. We thus generated
BG-1 clones that stably and strongly expressed GILZ,
named pGILZ clones. BG-1 clones stably transfected with
an empty vector, named CTRL clones, were used as con-
trol.
GILZ silencing
Small interfering RNA (siRNAs) duplexes were synthe-
sized and tested for specific inhibition of GILZ expression
as described previously [10]. BG-1 cells (5 × 105 cells/
well) were transfected with 4 μg/well GILZ siRNA (siG-
ILZ) or control siRNA (siCT), purchased from Qiagen
(Courtaboeuf, France), by the lipofectamine method
using X-tremeGENE siRNA transfection reagent according
to the manufacturer's instructions (Roche Diagnostics,
Meylan, France). Transfection efficiency was between 80%
and 90%, as assessed by using fluorescent random siRNA:
siRNA AlexaFluor 488 (Qiagen).
RT-PCR procedures
Total RNA was extracted using a RNeasy Mini kit (Qia-
gen). The RNA was transcribed into cDNA by reverse tran-
scription with random hexamers (Roche Diagnostics) and
Moloney murine leukemia virus (MMLV) reverse tran-
scriptase (Invitrogen). GILZ mRNA was quantified by real-
time PCR on a Light Cycler instrument (Roche Diagnos-
tics) using the FastStart DNA Master SYBER Green kit
(Roche Diagnostics) as described previously [9,10]. Val-
ues were normalized to those for β-actin mRNA and are
Table 2: Clinical and histological parameters of patients
Patient number Median Percentage Min-Max
Clinical parameters
Invasive ovarian tumors 50
Age (years) 57 [30-86]
Histologic types
Serous 26 52%
Endometrioid 8 16%
Mucinous 9 18%
Clear Cells 5 10%
Undifferentiated 2 4%
FIGO stages
FIGO stages IA-IC 14 (11 IA + 3 IC) 28%
FIGO stages IIA-IIC 4 (2 IIA + 2 IIC) 8%
FIGO stages IIIA-IIIC 30 (2 IIIA + 7 IIIB + 21 IIIC) 60%
FIGO stage IV 2 IV 4%
Histologic Grades
Grade 1 9 18%
Grade 2 11 22%
Grade 3 23 46%
undetermined 7 14%Molecular Cancer 2009, 8:83 http://www.molecular-cancer.com/content/8/1/83
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thus expressed as the GILZ/β-actin ratio. p21 and cyclin D1
mRNAs were assayed by semi-quantitative RT-PCR as
described previously [52]. The primers used were as fol-
lowing: GILZ (294 bp) sense 5'-TCTGCTTGGAGGGGAT-
GTGG-3', antisense 5'-ACTTGTGGGGATTCGGGAGC-3';
Cyclin D1 (413 bp) sense 5'-TGCATGTTCGT-
GGCCTCTAA-3', antisense 5'-CAGTCCGGGTCACACTT-
GAT-3'; p21 (331 bp) sense 5'-
CGACTGTGATGCGCTAATGG-3', antisense 5'-CCGTTT-
TCGACCCTGAGAG-3'; β-actin (237 bp) sense 5'-GGGT-
CAGAAGGATTCCTATG-3', antisense 5'-
GGTCTCAAACATGATCTGGG-3'.
[3H] thymidine uptake
Cells were seeded in triplicate on 96-well plates at a den-
sity of 1 × 104 cells/well in DMEM medium with 10% FBS.
Twenty-four hours later, [3H] thymidine (0.5 μCi/well)
(PerkinElmer, Boston, US) was added and the samples
incubated overnight. The radioactivity incorporated was
determined as described previously [52] and results are
expressed as counts per minute (cpm).
Western blot and immunoprecipitation
Cells (2 × 106) were lyzed as described previously [17].
Equivalent amounts of proteins were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), trans-
ferred to nitrocellulose membranes (Hybond-ECL, Amer-
sham, Saclay, France) and probed with rabbit polyclonal
Abs recognizing GILZ (Santa Cruz), AKT phosphorylated
at Ser473, total AKT, and ERK1/2 phosphorylated at Thr202/
204, and retinoblastoma phosphorylated at Ser807/811 (all
from Cell Signaling). Anti-cyclin D1 and anti-p21 mAbs
were purchased from Cell Signaling. Loading controls
used goat anti-β-actin Ab from Santa Cruz. Primary Abs
were visualized using HRP-conjugated anti-rabbit, anti-
mouse and anti-goat IgG (Santa Cruz) and enhanced
chemiluminescence detection (Amersham). ScanAnalysis
software (Biosoft, Cambridge, United Kingdom) was used
for densitometric analysis.
Total protein lysates from BG-1 clones were immunopre-
cipitated with polyclonal anti-AKT Ab (Santa Cruz) over-
night and then the immune complexes were precipitated
with protein G bound to sepharose beads (Sigma-
Aldrich). The immunoprecipitates were immunoblotted
with anti-GILZ Ab to investigate the presence of GILZ.
In Vitro kinase assay
The nonradioactive AKT kinase assay kit was used accord-
ing to the manufacturer's instructions (Cell Signaling).
Immobilized AKT mAb was used to immunoprecipitate
AKT from cell lysates and the samples subjected to an in
vitro kinase assay using GSK-3 fusion protein as a sub-
strate. Phosphorylation of GSK-3 was measured by west-
ern blotting using phosphorylated GSK-3α/β (Ser21/9) Ab
and chemiluminescent detection.
Cell-cycle analysis
BG-1 cells were synchronized by double thymidine block
as described previously [53]. After releasing the block in
DMEM-10% FBS, cell cycles were analyzed using propid-
ium iodide (PI) staining and fluorescence was measured
using a FACScan flow cytometer. Cell cycle profiles were
analyzed by ModFit Cell Cycle Analysis software.
Statistical analysis
StatEL statistical software (Adscience, Paris, France) was
used. The Spearman test was used to analyze the relation-
ship between GILZ and Ki-67 scores. The two-tailed
unpaired Student's t test was used to compare two groups
and the Kruskal Wallis test followed by Dunn's test was
used to compare several groups. Fisher's exact test was
used to compare the relationship between the expression
levels of GILZ and Ki-67 and of GILZ and p-AKT. Signifi-
cance was set at P < 0.05.
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